Several secretive and well-funded biotechs are sharing the first glimpses of data from a new suite of gene editing tools that ...
Drugmakers would have until 2032 to cut ties with WuXi AppTec and other Chinese life sciences companies, according to an ...
Bernie Sanders (I-VT) and Jeff Merkley (D-OR) accused a new US Chamber of Commerce coalition of attempting to “stymie the ...
Bluebird bio’s stock $BLUE jumped over 20% on Thursday following its first-quarter earnings release and the announcement of ...
Maze Therapeutics has found a new buyer for its Pompe disease candidate, five months after scrutiny from the Federal Trade ...
Takeda is shuttering its San Diego research site, the company confirmed to Endpoints News. The company told employees on ...
Ginkgo Bioworks is looking to cut expenses and personnel in an effort to return to profitability and break even by ...
As the head of the trade group BIO and a parent to children with a rare disease, John Crowley is personally and ...
Verona Pharma has secured up to $650 million to aid the potential launch of its COPD candidate ensifentrine. Under new ...
Lawmakers in the House Energy and Commerce Committee criticized the management of the national stockpile in a ...
Rapt Therapeutics said it will close and unblind two mid-stage trials in atopic dermatitis and asthma after they were put on ...
California biotech Attovia Therapeutics is back with a $105 million Series B just 11 months after unveiling with $60 million.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results